It is quite likely that we will trade at up to 20. We will get $65,000,000 in milestones and maybe $50,000,000 to $60,000,000 this year in royalties. EU approval and a partnership there will push us up even higher. However, once the trials on combinations begin and sales ramp up, the institutions will move in big time. The markets are even larger when the benefit to A1C is considered. This will drive drs prescribe, perhaps as much as boesity.